Tags

Type your tag names separated by a space and hit enter

Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease.
Thromb Res. 2004; 113(1):57-65.TR

Abstract

INTRODUCTION

Elevated levels of coagulation factor VII (FVII) have been associated with increased risk for myocardial infarction (MI). The R353Q polymorphism of the FVII gene has been shown to modify plasma levels of FVII, and has in some studies also been associated with reduced risk for MI.

OBJECTIVES

To examine the R353Q polymorphism of the FVII gene and the relation to myocardial infarction (MI), cardiovascular disease (CVD), and diabetes, and furthermore, to elucidate the association between the polymorphism and plasma levels of FVII coagulant activity (FVIIc), FVII antigen (FVIIag), activated FVII (FVIIa), and serum choline-containing phospholipids (PC).

METHODS

In 560 elderly men characterised as hypercholesterolemic in 1972, we examined the R353Q polymorphism by melting curve analysis after real-time PCR. In a subgroup of 205 individuals, FVIIc, FVIIag, FVIIa, and PC were analysed.

RESULTS

There were no significant associations between genotype and the disease states, although we observed a lower number of MI cases among subjects with the Q allele, compared to the RR individuals (14% vs. 19%). FVIIag and FVIIc levels were lower in RQ compared to RR subjects, whereas for FVIIa the opposite was observed (p<0.001 for all). PC correlated positively with FVIIag (r=0.24, p<0.001), but negatively with FVIIa (r=-0.25, p<0.001). No genotype specific interactions were found for the association between FVII and PC.

CONCLUSION

No significant associations between the R353Q polymorphism and MI, CVD, or diabetes were observed, although the polymorphism strongly influenced plasma levels of FVII. Serum PC correlated significantly with FVIIag and inversely with FVIIa, independently of genotype.

Authors+Show Affiliations

Center for Clinical Research, Ullevål University Hospital, Oslo, Norway. anja1@basalmed.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15081566

Citation

Lindman, Anja S., et al. "Coagulation Factor VII, R353Q Polymorphism, and Serum Choline-containing Phospholipids in Males at High Risk for Coronary Heart Disease." Thrombosis Research, vol. 113, no. 1, 2004, pp. 57-65.
Lindman AS, Pedersen JI, Arnesen H, et al. Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease. Thromb Res. 2004;113(1):57-65.
Lindman, A. S., Pedersen, J. I., Arnesen, H., Hjerkinn, E. M., Veierød, M. B., Prydz, H., & Seljeflot, I. (2004). Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease. Thrombosis Research, 113(1), 57-65.
Lindman AS, et al. Coagulation Factor VII, R353Q Polymorphism, and Serum Choline-containing Phospholipids in Males at High Risk for Coronary Heart Disease. Thromb Res. 2004;113(1):57-65. PubMed PMID: 15081566.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease. AU - Lindman,Anja S, AU - Pedersen,Jan I, AU - Arnesen,Harald, AU - Hjerkinn,Elsa M, AU - Veierød,Marit B, AU - Prydz,Hans, AU - Seljeflot,Ingebjørg, PY - 2003/12/04/received PY - 2004/02/02/revised PY - 2004/02/02/accepted PY - 2004/4/15/pubmed PY - 2004/11/13/medline PY - 2004/4/15/entrez SP - 57 EP - 65 JF - Thrombosis research JO - Thromb Res VL - 113 IS - 1 N2 - INTRODUCTION: Elevated levels of coagulation factor VII (FVII) have been associated with increased risk for myocardial infarction (MI). The R353Q polymorphism of the FVII gene has been shown to modify plasma levels of FVII, and has in some studies also been associated with reduced risk for MI. OBJECTIVES: To examine the R353Q polymorphism of the FVII gene and the relation to myocardial infarction (MI), cardiovascular disease (CVD), and diabetes, and furthermore, to elucidate the association between the polymorphism and plasma levels of FVII coagulant activity (FVIIc), FVII antigen (FVIIag), activated FVII (FVIIa), and serum choline-containing phospholipids (PC). METHODS: In 560 elderly men characterised as hypercholesterolemic in 1972, we examined the R353Q polymorphism by melting curve analysis after real-time PCR. In a subgroup of 205 individuals, FVIIc, FVIIag, FVIIa, and PC were analysed. RESULTS: There were no significant associations between genotype and the disease states, although we observed a lower number of MI cases among subjects with the Q allele, compared to the RR individuals (14% vs. 19%). FVIIag and FVIIc levels were lower in RQ compared to RR subjects, whereas for FVIIa the opposite was observed (p<0.001 for all). PC correlated positively with FVIIag (r=0.24, p<0.001), but negatively with FVIIa (r=-0.25, p<0.001). No genotype specific interactions were found for the association between FVII and PC. CONCLUSION: No significant associations between the R353Q polymorphism and MI, CVD, or diabetes were observed, although the polymorphism strongly influenced plasma levels of FVII. Serum PC correlated significantly with FVIIag and inversely with FVIIa, independently of genotype. SN - 0049-3848 UR - https://www.unboundmedicine.com/medline/citation/15081566/Coagulation_factor_VII_R353Q_polymorphism_and_serum_choline_containing_phospholipids_in_males_at_high_risk_for_coronary_heart_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049384804000738 DB - PRIME DP - Unbound Medicine ER -